Loading quotes...
Forecast
There is no analyst data available for this company.
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
Abivax reports loss per share of $1.71 in quarter ended June 30, 2026
Abivax released results for the quarter ended June 30, 2026, reporting a loss per share of $1.71. In the same quarter a year earlier, the loss was $0.86 per share. The stock fell by around 4.5%. » More on finanzen.net
Abivax to release quarterly results for period ended 30 June 2026 on 21 September 2026
Abivax will publish its balance sheet for the quarter ended 30 June 2026 on 21 September 2026. Six analysts expect on average a loss per share of -0.917 USD (prior year -0.860 USD). Seven analysts forecast revenue of around 0.8 million USD versus 0.0 million USD in the year-ago quarter. For the current fiscal year analysts see on average a loss per share of -3.762 USD (prior year -5.450 USD) and annual revenue of 4.4 million USD on average. » More on finanzen.net
Abivax publishes quarterly results for 30.06.2026, analysts see another loss
Abivax will present the quarterly results for the period ending 30.06.2026 on 21.09.2026. Six analysts expect a quarterly loss per share of -0.801 EUR (previous year: -0.760 EUR) and seven analysts estimate revenue of 0.7 million EUR (previous year: 0.0 million EUR). For the fiscal year, 14 analysts on average forecast a loss per share of -3.291 EUR (previous year: -4.830 EUR) with average revenue of 3.8 million EUR (previous year: 0.0 million EUR). » More on finanzen.net
Abivax expects Q2 EPS of -0.839 EUR and revenue of about 0.7 million EUR
Abivax is expected to publish its quarterly figures for 30/06/2026 on 21/09/2026. Analysts on average forecast earnings of -0.839 EUR per share for the quarter (previous year: -0.760 EUR) and revenue of around 0.7 million EUR (previous year: 0.0 million EUR). For the current fiscal year, the average analyst outlook is a loss of -3.309 EUR per share and revenue of about 3.8 million EUR. » More on finanzen.net
Abivax expects quarterly results on September 21, 2026 with another EPS loss
For the quarter for which Abivax will report figures on September 21, 2026, five analysts forecast an average earnings per share of -0.959 USD, a decline of 11.51% from -0.860 USD a year earlier. Six analysts expect revenue of on average 0.8 million USD versus 0.0 million in the year‑ago quarter. For the fiscal year, 13 analysts on average forecast a loss per share of -3.778 USD (prior year -5.450 USD) and 14 analysts see revenue at an average of 4.4 million USD. » More on finanzen.net
Financials
| (EUR) | December 2025 | YoY |
|---|---|---|
| Revenue | -2.02m | - |
| Gross profit | -3.09m | - |
| Net profit | -235.32m | - |
| EBITDA | -155.96m | - |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €6.93bn |
Number of shares | 87.55m |
52-week high/low | €139.00 - €60.70 |
| Dividends | No |
Beta | -0.21 |
P/E ratio | -16.79 |
PEG ratio | 0.30 |
P/B ratio | 17.20 |
P/S ratio | -3,433.08 |
Company profile
ABIVAX Société Anonyme discovers and optimizes drugs for the treatment of inflammatory diseases, infectious diseases, and cancer in France. Its principal products include ABX464 that is in Phase IIb clinical trials for the treatment of ulcerative colitis and Crohn's Disease, as well as for COVID-19; Phase IIa clinical trial for the treatment of rheumatoid arthritis diseases; and has completed Phase IIa clinical trial for the treatment of viral remission in patients with HIV. It also develops ABX 196, an immune enhancer candidate that is in Phase 1/2 clinical trials for the treatment of hepatocellular cancer. In addition, the company engages in the research programs for the treatment of Dengue fever, influenza, and respiratory syncytial virus. ABIVAX Société Anonyme has license contracts with the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. The company was incorporated in 2013 and is headquartered in Paris, France.
| Name | Abivax |
| CEO | Marc de Garidel |
| Headquarters | Paris,
if France |
| Website | |
| IPO | 26/06/2015 |
| Employees | 69 |
Ticker symbols
| Exchange | Symbol |
|---|---|
London Stock Exchange | 0RA9.L |
Euronext | ABVX.PA |
Pnk | AAVXF |
Frankfurt | 2X1.F |
Düsseldorf | 2X1.DU |
London | 0RA9.L |
Paris | ABVX.PA |
München | 2X1.MU |